0000000000516183

AUTHOR

Fulvio Braido

showing 57 related works from this author

RHINASTHMA-Adolescents: a new quality of life tool for patients with respiratory allergy

2014

Background: Specific instruments for health-related quality of life (HRQoL) assessment in adolescents with rhinoconjunctivitis or asthma are available. None of them evaluates rhinitis and asthma together, although they often coexist. Our aim was to validate a HRQoL questionnaire for adolescents with rhinoconjunctivitis, asthma, or both. Methods: A pool of 38 items covering the main symptoms and problems related to respiratory allergy was generated based on literature review, clinical experience, and unstructured interviews to 54 adolescents. The items were randomly listed and presented to 88 consecutive outpatients (44 M; mean age 15.2 3.1). Patients had to indicate which item they had expe…

MaleQuestionnairesadolescents; asthma; health-related quality of life; rhinitis; Conjunctivitis; Female; Humans; Male; Respiratory Hypersensitivity; Young Adult; Quality of Life; QuestionnairesImmunologyasthmaConjunctivitishealth-related quality of lifeYoung Adultrhinitisadolescents; asthma; health-related quality of life; rhinitisadolescentSurveys and QuestionnairesPediatrics Perinatology and Child HealthRespiratory HypersensitivityQuality of LifeImmunology and AllergyHumansFemaleadolescents
researchProduct

Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution

2022

Although bronchodilators are the cornerstone in chronic obstructive pulmonary disease (COPD) therapy, the treatment with a single-agent bronchodilator may not provide adequate symptoms control in COPD. The combination of drugs with different mechanisms of action may be more effective in inducing bronchodilation and preventing exacerbations, with a lower risk of side-effects in comparison with the increase of the dose of a single molecule. Several studies comparing the triple therapy with the association of long-acting ß2 agonist (LABA)/inhaled corticosteroid (ICS) or long-acting muscarinic antagonist (LAMA)/LABA reported improvement of lung function and quality of life. A significant reduc…

Pulmonary and Respiratory MedicineRC705-779ReviewMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioCOPD inhaled extrafine formulation triple therapyinhaled extrafine formulationBronchodilator AgentsDrug CombinationsPulmonary Disease Chronic ObstructiveDiseases of the respiratory systemtriple therapyFormoterol FumarateAdministration InhalationQuality of LifeCOPDHumansDrug Therapy CombinationPharmacology (medical)Adrenergic beta-2 Receptor AgonistsTherapeutic Advances in Respiratory Disease
researchProduct

Corrigendum to “Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up” [Respir. Med. 153 (2019) 68–75]

2019

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCOPDbusiness.industryHealth caremedicineIntensive care medicinebusinessmedicine.diseaseRespiratory Medicine
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations

2017

Asthma has been demonstrated to be as common in the elderly as in younger age groups. Although no specific recommendations exist to manage the disease differently in older individuals, functional features and clinical presentations may be affected by age per se, and by age-related conditions, such as comorbidities and polypharmacy. In this review article, we aimed to explore the efficacy and safety in elderly asthmatic patients of one of the most currently used inhaled treatments for asthma, that is, the fixed-dose combination of budesonide/formoterol. We attempted to address some practical questions that are relevant to the daily practice of clinicians. We focused on the efficacy and real-…

BudesonideGeriatrics & GerontologyDatabases Factuallaw.invention0302 clinical medicineRandomized controlled trialRELIEVER THERAPYlawBudesonide Formoterol Fumarate Drug CombinationDrug InteractionsPharmacology (medical)Anti-Asthmatic AgentsPharmacology & Pharmacy030212 general & internal medicineEMPHYSEMATOUS LUNGSGeriatricsPRIMARY-CAREGeriatrics and Gerontology Pharmacology (medical)Middle AgedRANDOMIZED CONTROLLED-TRIALSINGLE INHALERTreatment OutcomeDrug InteractionPractice Guidelines as TopicLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioOBSTRUCTIVE PULMONARY-DISEASE03 medical and health sciencesAdministration InhalationmedicineAnti-Asthmatic AgentHumansOLDER-PEOPLEIntensive care medicineAgedAsthmaPolypharmacyAIRWAY CLEARANCEScience & Technologybusiness.industryDRY POWDER INHALERSmedicine.diseaseAsthma030228 respiratory systemBudesonide/formoterolLUNG DEPOSITIONGeriatricsPhysical therapyIndacaterol1115 Pharmacology And Pharmaceutical SciencesFormoterolGeriatrics and GerontologybusinessDrugs & Aging
researchProduct

Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT)study follow-up

2019

Abstract Background Chronic obstructive pulmonary disease (COPD) is characterised by recurring exacerbations. We estimated the costs of healthcare resources for COPD management funded by the Italian National Healthcare Service (INHS) for one year. Methods We examined the demographic, clinical, and economic variables at enrolment and follow-up visits (at 6 and 12 months) of COPD patients participating in the SAT study and referred to 20 Italian pulmonary centres with different institutional characteristics. Costs were expressed in Euro (€) 2018. A random effects log-linear panel regression model was performed to predict the average cost per patient. Results Most of the centres were public in…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyCost-Benefit AnalysisSocio-culturaleMuscarinic AntagonistsPersonal SatisfactionSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineHealth careMedicineHumansCOPD management Econometric model Healthcare costs030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAverage costAgedAged 80 and overCOPDbiologyCOPD management; Econometric model; Healthcare costsbusiness.industryCOPD managementOxygen Inhalation TherapyRegression analysisHealth Care CostsLamaMiddle AgedHealthcare costsbiology.organism_classificationmedicine.diseaseRandom effects modelBronchodilator AgentsPatient Care ManagementRespiratory Function TestsEconometric model030228 respiratory systemItalyEmergency medicinePublic universityDisease ProgressionPatient ComplianceDrug Therapy CombinationbusinessPanel dataFollow-Up Studies
researchProduct

What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis

2020

Abstract Background The choice of inhaler device for asthma patients depends upon multiple attributes. We investigated factors that may drive general practitioners (GPs) and respiratory specialists in the prescription of inhaler devices for asthma patients who initiated inhalation therapy. Methods We retrospectively analysed prescriptions by GPs and respiratory specialists to asthma patients commencing inhaled corticosteroid/long-acting β2-agonist combination therapy available as both pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). Patient characteristics were compared by device and multivariate analysis was used to model the likelihood of receiving a pMDI as oppos…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyMultivariate analysisSettore MED/10 - Malattie Dell'Apparato RespiratorioGeneral practitioner03 medical and health sciencesdry powder inhaler0302 clinical medicineInhalersAdrenal Cortex HormonesAdrenergic beta-2 Receptor AntagonistsAsthma controlGeneral practitionersAdministration InhalationRetrospective analysisMedicine030212 general & internal medicineMetered Dose InhalersMedical prescriptionAsthmaRetrospective Studiesbusiness.industryInhalerdry powder inhalersInhalerOdds ratiomedicine.diseaseConfidence intervalAsthmaPressurised metered-dose inhalerAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialistsPrescriptions030228 respiratory systemRespiratory specialistsInhalationDelayed-Action PreparationsEmergency medicineAdministrationPressurised metered-dose inhalersbusinessAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialists; Administration Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagonists; Asthma; Delayed-Action Preparations; Retrospective Studies; Dry Powder Inhalers; Metered Dose Inhalers; Prescriptions
researchProduct

Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic…

2015

Inhaled corticosteroids (ICS) are frequently recommended for the treatment of asthma and COPD, often in combination with long-acting beta2-agonists (LABA), depending on the severity of the disease and/or on the specific phenotype. Several ICS/LABA combinations are currently available that differ in their pharmacokinetic characteristics and dose of both components. Thus, this review assesses differences in the efficacy and the safety profiles of the ICS components in the two more frequently used ICS/LABA combinations (budesonide/formoterol and fluticasone/salmeterol) for the management of COPD. Whereas the basic mechanism of action is similar for all ICS (binding with the intracellular gluco…

BudesonideAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classPopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioBudesonide; COPD; Fluticasone; Pneumonia; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Drug Combinations; Glucocorticoids; Humans; Pulmonary Disease Chronic Obstructive; Quality of Life; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)Pulmonary DiseasePulmonary Disease Chronic ObstructiveGlucocorticoidInternal medicineDrug CombinationAdministration InhalationmedicineBudesonide; COPD; Fluticasone; Pneumonia; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical)HumansCOPDPharmacology (medical)educationBudesonideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAsthmaFluticasoneeducation.field_of_studyCOPDbusiness.industryBiochemistry (medical)Pneumoniamedicine.diseaserespiratory tract diseasesDrug CombinationsInhalationAnesthesiaAdministrationQuality of LifeCorticosteroidFluticasoneFormoterolSalmeterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugHuman
researchProduct

Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease

2020

<b><i>Background:</i></b> Disease awareness is a challenge in the management of chronic obstructive pulmonary disease (COPD). <b><i>Objectives:</i></b> The aim of this analysis was to explore the association between COPD optimal and suboptimal awareness, clinical parameters, and the following patient-reported outcomes: modified Medical Research Council (mMRC), Treatment Satisfaction Questionnaire (TSQM-9), COPD Assessment Test (CAT), Morisky Medication-Taking Adherence Scale (MMAS-4), and Brief Illness Perception Questionnaire (B-IPQ). <b><i>Methods:</i></b> This post hoc analysis of the SAT study included all enrolled …

Pulmonary and Respiratory MedicineMaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyChronic ObstructiveHealth BehaviorClinical InvestigationsPulmonary diseaseSocio-culturaleDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Indexchronic obstructive pulmonary diseaseTreatment satisfactionIllness perceptionsPulmonary DiseasePulmonary Disease Chronic ObstructiveDiagnostic Self EvaluationInternal medicineSurveys and QuestionnairesPost-hoc analysismedicineSettore MED/10HumansAdherence awareness chronic obstructive pulmonary disease patient-reported outcomesIn patientawarenessPatient Reported Outcome MeasuresAgedCOPDPracticebusiness.industryHealth KnowledgeSelf-Managementmedicine.diseaseSymptom Flare UpAdherence; Awareness; Chronic obstructive pulmonary disease; Patient-reported outcomes; Aged; Female; Health Knowledge Attitudes Practice; Humans; Italy; Male; Patient Reported Outcome Measures; Patient Satisfaction; Severity of Illness Index; Surveys and Questionnaires; Symptom Flare Up; Diagnostic Self Evaluation; Health Behavior; Pulmonary Disease Chronic Obstructive; Self-Management; Treatment Adherence and ComplianceTreatment Adherence and ComplianceItalyPatient SatisfactionAdherencepatient-reported outcomesAttitudesCopd assessment testFemalebusiness
researchProduct

WITHDRAWN: Scaling up strategies of the Chronic Respiratory Disease programme of the European Innovation Partnership on Active and Healthy Ageing (Ac…

2017

Gerontologymedicine.medical_specialtybusiness.industryRespiratory diseaseAlternative medicinemedicine.disease03 medical and health sciences0302 clinical medicine030228 respiratory systemGeneral partnershipAction planmedicineGeneral Earth and Planetary Sciences030212 general & internal medicineHealthy ageingbusinessGeneral Environmental ScienceAlergologia Polska - Polish Journal of Allergology
researchProduct

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life

2016

Marco Contoli,1 Paolo Solidoro,2 Fabiano Di Marco,3,4 Nicola Scichilone,5 Angelo Corsico,6 Fulvio Braido,7 Pierachille Santus4,8 1Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 2Cardiovascular and Thoracic Department, Città della Salute, Turin, Italy; 3Department of Health Sciences, University of Milan, Milan, Italy; 4Respiratory Unit, San Paolo Hospital, Milan, Italy; 5Department of Internal Medicine, Section of Pulmonology (DIBIMIS), University of Palermo, Palermo, Italy; 6Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 7Allergy and Respiratory Diseases Clinic, DIMI, University of G…

Time FactorsReviewdaily symptomsAclidinium; COPD; Daily symptoms; LAMA; Quality of life; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational HealthSeverity of Illness IndexPulmonary Disease Chronic Obstructive0302 clinical medicineBronchodilatorMedicine030212 general & internal medicineLungCOPDHealth PolicyTropaneLAMAGeneral MedicineBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeTolerabilityChronic inflammatory responsePublic HealthHumanPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyTime Factormedicine.drug_classBronchoconstrictionSocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease03 medical and health sciencesAclidinium bromideaclidiniumAclidinium; COPD; Daily symptoms; LAMA; Quality of life; Bronchoconstriction; Bronchodilator Agents; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Recovery of Function; Severity of Illness Index; Time Factors; Treatment Outcome; Tropanes; Quality of LifeInternal medicineSeverity of illnessAnticholinergicCOPDHumansAdverse effectBronchodilator Agentlcsh:RC705-779business.industryEnvironmental and Occupational HealthDaily symptomPublic Health Environmental and Occupational Healthlcsh:Diseases of the respiratory systemRecovery of Functionmedicine.diseasequality of life030228 respiratory systemPhysical therapybusinessTropanesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

Minimal clinically important difference for asthma endpoints: an expert consensus report

2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient repo…

Asthma asthma management minimal clinically important difference end-pointsPulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusDelphi TechniqueEndpoint DeterminationBronchoconstrictionMEDLINEDelphi methodSocio-culturaleSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOminimal clinically important difference; asthma; lung function; biomarkersMCID03 medical and health sciences0302 clinical medicinePredictive Value of TestsmedicineHumansAnti-Asthmatic Agents030212 general & internal medicineDisease management (health)Intensive care medicineLungAsthmalcsh:RC705-779business.industryMinimal clinically important differenceminimal clinically important differenceExpert consensusend-pointslcsh:Diseases of the respiratory systemmedicine.diseaseMCID asthmaAsthmaTreatment Outcome030228 respiratory systemPredictive value of testsEndpoint DeterminationInflammation MediatorsSymptom AssessmentbusinessBiomarkersasthma managementEuropean Respiratory Review
researchProduct

Cost-description and multiple imputation of missing values: theSATisfaction and adherence to COPD treatment(SAT) study

2018

Aim:This article reports on a retrospective quarterly cost description (CD) performed on 401 patients with stable chronic obstructive pulmonary disease (COPD) at enrolment in the national, multicen...

COPDmedicine.medical_specialtymultiple imputationbusiness.industry030503 health policy & servicesHealth PolicySAT studyPulmonary diseasemedicine.diseaseMissing datahumanitiesCOPD Italy SAT study cost description multiple imputation03 medical and health sciences0302 clinical medicineItalyInternal medicinemedicineCOPD030212 general & internal medicine0305 other medical sciencebusinesscost descriptionGlobal & Regional Health Technology Assessment: Italian; Northern Europe and Spanish
researchProduct

Late Breaking Abstract - Relationship between clinical features and mortality in a cohort of COPD patients

2021

Background: Chronic obstructive pulmonary disease (COPD) is a progressive disease with poor outcomes, including a high mortality. GULP is a multicenter Italian study that described clinical characteristics, exacerbation rates and survival of a cohort of COPD patients, as part of AstraZeneca’s AvoidEX program. Aims and objectives: To evaluate whether the clinical profile of subjects enrolled in the GULP study predicts mortality on a period of 3 years. Methods: Post-hoc analysis of an observational, multicenter, retrospective study. Patients were stratified according to survival status: alive (A) and dead (D). Clinical characteristics, comorbidities and exacerbation rates were reported in the…

COPDmedicine.medical_specialtyExacerbationbusiness.industryRetrospective cohort studyDiseaseOdds ratiomedicine.diseaseInternal medicineHeart failureCohortmedicinebusinessProgressive diseaseMonitoring airway disease
researchProduct

Chronic obstructive lung disease “expert system”: validation of a predictive tool for assisting diagnosis

2018

Fulvio Braido,1 Pierachille Santus,2 Angelo Guido Corsico,3 Fabiano Di Marco,4 Giovanni Melioli,5 Nicola Scichilone,6 Paolo Solidoro7 1Department of Internal Medicine, IRCCS San Martino di Genova University Hospital, Genoa, Italy; 2Department of Biomedical and Clinical Sciences, University of Milan, Division of Respiratory Diseases, “L. Sacco” University Hospital, ASST Fatebenefratelli-Sacco, Milan, Italy; 3Department of Internal Medicine and Therapeutics, Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, University of Pavia, Italy; 4Department of Health Sciences, University of Milan, San Paolo Hospital, Milan, Italy; 5Center for Precision Medici…

medicine.medical_specialtyValidation studyConcordance analysisbusiness.industryGeneral MedicinePrimary careInternational Journal of Chronic Obstructive Pulmonary Diseasemedicine.diseasecomputer.software_genreObstructive lung diseaseExpert system03 medical and health sciences0302 clinical medicine030228 respiratory systemSample size determinationConcomitantEmergency medicinemedicine030212 general & internal medicineMedical diagnosisbusinesscomputerInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Effects of a structured educational intervention in moderate-to-severe elderly asthmatic subjects.

2019

Background: Adherence to inhaled drugs is linked to patients’ satisfaction with their device, and an incorrect use can negatively affect the outcomes of asthma treatment. We speculated that this is particularly true in elderly asthmatic subjects. Aim: We performed a national pre-post interventional multicentre study, enrolling moderate-to-severe asthmatic subjects aged ≥65 ​years treated with fixed inhaled combination drugs by dry powder inhaler (DPI) or pressurized metered dose inhaler (pMDI). Adherence and critical errors were evaluated by means of validated questionnaires at first visit (V1) and after 3–6 months (V2). At V1, subjects underwent intensive training on the correct use of the…

Vital capacityACT asthma control testExacerbationSAE severe asthma exacerbationSF12chlorofluorocarbonsmental health composite scoreEDUCA elderly and device use in chronic asthmaPCS physical health composite scoreACT asthma control test; AHDS hospital anxiety depression scale; Asthma; CFC chlorofluorocarbons; Device misuse; EDUCA elderly and device use in chronic asthma; Education; Elderly; FEV1 forced expiratory volume 1s second; FVC forced vital capacity; ICS inhaled corticosteroids; LABA long-acting β2 agonist; LAMA long-acting muscarinic antagonists; MCS mental health composite score; PCS physical health composite score; PROs patient-reported outcomes; SAE severe asthma exacerbation; SF12 short form health survey; mMRC modified medical research councilEDUCAFEV10302 clinical medicineElderlyImmunology and AllergyMedicine030223 otorhinolaryngologybiologymMRC modified medical research councilsevere asthma exacerbationmodified medical research councilLAMASAELamaelderly and device use in chronic asthmaMetered-dose inhalerDry-powder inhalerDevice misusePROs patient-reported outcomesCFCPCSpatient-reported outcomesmMRClcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinelong-acting β2 agonistmedicine.medical_specialtyImmunologyLABAphysical health composite scoreArticleLAMA long-acting muscarinic antagonistsAHDSEducation03 medical and health sciencesFEV1/FVC ratiolong-acting muscarinic antagonistsforced vital capacitySF12 short form health surveyAsthma; Device misuse; Education; ElderlyInternal medicineMCS mental health composite scoreforced expiratory volume 1s secondAsthmabusiness.industryFEV1 forced expiratory volume 1s secondInhalerasthma control testbiology.organism_classificationmedicine.diseaseCFC chlorofluorocarbonsACTICS inhaled corticosteroidsFVCAsthmaMCShospital anxiety depression scale030228 respiratory systemICSAHDS hospital anxiety depression scaleFVC forced vital capacityPROsshort form health surveyinhaled corticosteroidslcsh:RC581-607businessLABA long-acting β2 agonistThe World Allergy Organization journal
researchProduct

Disability in moderate chronic obstructive pulmonary disease: Prevalence, burden and assessment-results from a real-life study

2014

<b><i>Background:</i></b> The role of disability and its association with patient-reported outcomes in the nonsevere forms of chronic obstructive pulmonary disease (COPD) has never been explored. <b><i>Objectives:</i></b> The aim of this study was to assess, in a cross-sectional real-life study, the prevalence and degree of disability in moderate COPD patients and to assess its association with health status, illness perception, risk of death and well-being. <b><i>Methods:</i></b> Moderate COPD outpatients attending scheduled visits were involved in a quantitative research program using a questionnaire-based data collec…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveActivities of daily livingCross-sectional studyHealth StatusPulmonary diseaseChronic obstructive pulmonary disease; Disability; Patient-reported outcomes; Activities of Daily Living; Aged; Cross-Sectional Studies; Disability Evaluation; Female; Health Status; Humans; Italy; Male; Middle Aged; Pulmonary Disease Chronic Obstructive; Pulmonary and Respiratory MedicineSettore MED/10 - Malattie Dell'Apparato RespiratorioChronic obstructive pulmonary disease; Disability; Patient-reported outcomes; Activities of Daily Living; Aged; Cross-Sectional Studies; Disability Evaluation; Female; Health Status; Humans; Italy; Male; Middle Aged; Pulmonary Disease Chronic Obstructive; Pulmonary and Respiratory Medicine; Medicine (all)Illness perceptionsPulmonary DiseasePulmonary Disease Chronic ObstructiveDisability EvaluationActivities of Daily LivingMedicineHumansDisease burdenAgedCOPDDisabilityPatient-reported outcomesbusiness.industryMedicine (all)Chronic obstructive pulmonary diseaseMiddle Agedmedicine.diseaseCross-Sectional StudiesItalyPhysical therapyFemaleRisk of deathbusinessLife study
researchProduct

The Effect of Intranasal Corticosteroids on Asthma Control and Quality of Life in Allergic Rhinitis with Mild Asthma

2011

BACKGROUND: The mechanisms through which rhinitis affects asthma have not been completely elucidated. We explored whether the effect of nasal treatment on asthma control and respiratory-related quality of life (HRQoL) is mediated by inflammatory changes of the upper and lower airways. METHODS: Allergic rhinitics with mild asthma were randomized to a 14-day treatment period with either nasal budesonide 100 mug, 1 puff per nostril twice a day, or placebo. Clinical, functional, and biological evaluations were performed before and after treatment. RESULTS: Twenty subjects (M/F: 10/10; age: 31 +/- 15 years; mean +/- SD) were enrolled, and a total of 17 individuals completely participated in the …

MaleBudesonideNasal cavityrespiratory musclesVital CapacityPediatricsQuality of lifeSurveys and QuestionnairesImmunology and AllergypainBudesonidepostureRhinitisevaluationPerinatology and Child Healthrespiratory systemRespiratory Function Testsasmamedicine.anatomical_structureIntranasalAnesthesiaAdministrationFemaleNasal Cavitymedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyRhinitis Allergic PerennialNostrilMaximal Midexpiratory Flow RateSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboasthma; evaluation; musculoskeletal; pain; posture; respiratory muscles; Administration Intranasal; Adult; Asthma; Budesonide; Eosinophils; Female; Glucocorticoids; Humans; Male; Maximal Midexpiratory Flow Rate; Nasal Cavity; Nasal Lavage; Quality of Life; Rhinitis Allergic Perennial; Rhinitis Allergic Seasonal; Surveys and Questionnaires; Vital Capacity; Respiratory Function Tests; Pediatrics Perinatology and Child Health; Immunology and Allergy; Pulmonary and Respiratory MedicineAllergicInternal medicinemedicineHumansGlucocorticoidsAdministration IntranasalAsthmaSeasonalmusculoskeletalbusiness.industryRhinitis Allergic Seasonalasthmamedicine.diseasePerennialrespiratory tract diseasesEosinophilsPediatrics Perinatology and Child HealthNasal LavageQuality of LifeNasal LavageNasal administrationbusinessJournal of Asthma
researchProduct

Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives.

2018

Approximately 5%-10% of asthmatics suffer from severe asthma. New biological treatments represent a great opportunity to reduce asthma burden and to improve asthma patients' lives. Reslizumab will soon be available in several European countries. This anti-IL-5 IgG4/kappa monoclonal antibody, administered intravenously at a dose of 3 mg/kg over 20-50 minutes every 4 weeks, has been shown to be safe and effective in patients with 400 eosinophils/mu L or more in their peripheral blood. The clinical effects in reducing asthma exacerbations and in improving the quality of life and lung function are clear, but further research is needed to determine the best biological compound for a specific clu…

Drugmedicine.medical_specialtymedia_common.quotation_subjectReview030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato Respiratoriopatient-reported outcomeasthma; patient-reported outcomes; personalized medicine; reslizumabPathogenesis030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineReslizumabInternal medicinemedicineAsthmatic patientPathologicalAsthmamedia_commonbusiness.industrypersonalized medicineasthmamedicine.diseasereslizumabpatient-reported outcomesPersonalized medicinebusinessMepolizumabmedicine.drugPatient related outcome measures
researchProduct

Asthma management in a specialist setting: Results of an Italian Respiratory Society survey.

2017

Abstract Background Asthma considerably impairs patients' quality of life and increases healthcare costs. Severity, morbidity, and degree of disease control are the major drivers of its clinical and economic impact. National scientific societies are required to monitor the application of international guidelines and to adopt strategies to improve disease control and better allocate resources. Aim to provide a detailed picture of the characteristics of asthma patients and modalities of asthma management by specialists in Italy and to develop recommendations for the daily management of asthma in a specialist setting. Method: A quantitative research program was implemented. Data were collected…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyConcordanceSocio-culturalePractice PatternsSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Retrospective StudieSurveys and QuestionnairesSeverity of illnessHealth caremedicineSurveys and QuestionnaireHumansPharmacology (medical)030212 general & internal medicinePractice Patterns Physicians'Adult; Aged; Asthma; Female; Humans; Italy; Male; Middle Aged; Practice Patterns Physicians'; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Quality of Life; SpecializationAsthmaAgedRetrospective StudiesModalitiesPhysicians'business.industryBiochemistry (medical)Retrospective cohort studyMiddle Agedmedicine.diseaseAsthmaPulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)030228 respiratory systemItalyTest scoreFamily medicinePhysical therapyQuality of LifeFemalebusinessHumanSpecializationPulmonary pharmacologytherapeutics
researchProduct

Withdrawal of inhaled corticosteroids in COPD: A meta-analysis

2017

Background Conflicting findings exist on the benefit of withdrawal of inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD). We performed a quantitative synthesis in order to assess real impact of ICS discontinuation in COPD patients. Methods We carried out a meta-analysis via random-effects model on the available clinical evidence to evaluate the effect of ICS discontinuation in COPD. Randomized clinical trials and observational real-life studies investigating the effects of ICS withdrawal on the risk of COPD exacerbation, lung function (forced expiratory volume in 1 s [FEV1]) and quality of life (St. George's Respiratory Questionnaire [SGRQ]) were identified by sear…

Pulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classSocio-culturaleSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.invention03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineGlucocorticoidQuality of lifeRandomized controlled triallawInhaled corticosteroidForced Expiratory VolumeAdministration InhalationmedicineHumansPharmacology (medical)030212 general & internal medicineIntensive care medicineGlucocorticoidsRandomized Controlled Trials as TopicRespiratory Function TestCOPDInhaled corticosteroidsbusiness.industryChronic obstructive pulmonary diseaseBiochemistry (medical)medicine.diseaseRespiratory Function TestsDiscontinuationrespiratory tract diseasesChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal030228 respiratory systemWithholding TreatmentMeta-analysisRelative riskWithdrawalQuality of LifeCorticosteroidObservational studyChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)businessHuman
researchProduct

Oxidative Stress and Respiratory System: Pharmacological and Clinical Reappraisal of N-Acetylcysteine

2014

Abstract The large surface area for gas exchange makes the respiratory system particularly susceptible to oxidative stress-mediated injury. Both endogenous and exogenous pro-oxidants (e.g. cigarette smoke) trigger activation of leukocytes and host defenses. These mechanisms interact in a ìmultilevel cycleî responsible for the control of the oxidant/antioxidant homeostasis. Several studies have demonstrated the presence of increased oxidative stress and decreased antioxidants (e.g. reduced glutathione [GSH]) in subjects with chronic obstructive pulmonary disease (COPD), but the contribution of oxidative stress to the pathophysiology of COPD is generally only minimally discussed. The aim of t…

Pulmonary and Respiratory MedicineChronic ObstructiveAntioxidantantioxidantNeutrophilsmedicine.medical_treatmentAntioxidant; Copd exacerbation; Lung function; Small airways; Acetylcysteine; Antioxidants; Bronchitis Chronic; Disease Progression; Expectorants; Forced Expiratory Volume; Hospitalization; Humans; Macrophages; Neutrophils; Pulmonary Disease Chronic Obstructive; Reactive Oxygen Species; Respiratory Physiological Phenomena; Oxidative Stress; Pulmonary and Respiratory MedicineAntioxidant; Copd exacerbation; Lung function; Small airways; Acetylcysteine; Antioxidants; Bronchitis Chronic; Disease Progression; Expectorants; Forced Expiratory Volume; Hospitalization; Humans; Macrophages; Neutrophils; Pulmonary Disease Chronic Obstructive; Reactive Oxygen Species; Respiratory Physiological Phenomena; Oxidative StressOxidative phosphorylationReviewSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_causeAntioxidantsAcetylcysteinePulmonary Diseasechemistry.chemical_compoundPulmonary Disease Chronic ObstructiveCOPD exacerbationForced Expiratory VolumemedicineHumansRespiratory systemChronicBronchitisExpectorantschemistry.chemical_classificationCOPDReactive oxygen speciessmall airwaysbusiness.industryMacrophageslung functionGlutathionemedicine.diseaseAcetylcysteineBronchitis ChronicHospitalizationOxidative StresschemistryImmunologyDisease ProgressionRespiratory Physiological PhenomenabusinessReactive Oxygen SpeciesOxidative stressmedicine.drug
researchProduct

Is Health-Related Quality of Life Associated with Upper and Lower Airway Inflammation in Asthmatics?

2013

Background.Allergic diseases impair health-related quality of life (HR-QoL). However, the relationship between airway inflammation and HR-QoL in patients with asthma and rhinitis has not been fully investigated. We explored whether the inflammation of upper and lower airways is associated with HR-QoL.Methods.Twenty-two mild allergic asthmatics with concomitant rhinitis (10 males, 38 ± 17 years) were recruited. The Rhinasthma was used to identify HR-QoL, and the Asthma Control Test (ACT) was used to assess asthma control. Subjects underwent lung function and exhaled nitric oxide (eNO) test, collection of exhaled breath condensate (EBC), and nasal wash.Results.The Rhinasthma Global Summary sc…

AdultMaleQuality of lifeArticle SubjectAsthma; Quality of life; Airway inflammationlcsh:MedicineInflammationSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideGeneral Biochemistry Genetics and Molecular BiologyNitric oxideAllergic inflammationchemistry.chemical_compoundSurveys and QuestionnairesmedicineHumansExhaled breath condensateRespiratory systemLungRespiratory Function Tests; Questionnaires; Humans; Quality of Life; Asthma; Health; Inflammation; Nitric Oxide; Lung; Adult; Pulmonary Alveoli; Biological Markers; Female; MaleAsthmaRespiratory Function TestInflammationLungGeneral Immunology and Microbiologybusiness.industryQuestionnairelcsh:RGeneral Medicinerespiratory systemmedicine.diseaseAsthmaRespiratory Function Testsrespiratory tract diseasesPulmonary Alveolimedicine.anatomical_structurechemistryHealthImmunologyExhaled nitric oxideBiological MarkerClinical StudyFemalemedicine.symptombusinessBiomarkersHumanAirway inflammationBioMed Research International
researchProduct

Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?

2015

Inhalation is the preferred route of drug administration in chronic respiratory diseases because it optimises delivery of the active compounds to the targeted site and minimises side effects from systemic distribution. The choice of a device should be made after careful evaluation of the patient's clinical condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inhalation manoeuvre and to generate sufficient inspiratory flow. These patient factors must be aligned with the specific advantages and limitations of each inhaler when making this important choice. Finally, adherence to treatment is not the responsibility of the patient alone, but should …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveSocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Anti-asthmatic AgentMedication AdherencePulmonary DiseasePulmonary Disease Chronic ObstructiveSuspensionsAdministration InhalationmedicineCOPDHumansPharmacology (medical)Anti-Asthmatic AgentsMetered Dose InhalersRespiratory systemParticle SizeIntensive care medicineAsthmaAdherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)COPDInhalationbusiness.industryMedicine (all)InhalerNebulizers and VaporizersBiochemistry (medical)Adherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)InhalerDry Powder InhalersAirway obstructionmedicine.diseaseAsthmaSolutionsInhalationAdherenceAdministrationAdherence; Asthma; COPD; InhalerbusinessPulmonary pharmacologytherapeutics
researchProduct

The anti-inflammatory properties of tiotropium

2018

BenzoxazinePulmonary and Respiratory Medicinemedicine.drug_classbusiness.industryScopolamine DerivativesPulmonary diseaseTiotropium bromidePharmacologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-inflammatory03 medical and health sciencesAnti-Inflammatory AgentPulmonary Disease Chronic ObstructiveScopolamine Derivative0302 clinical medicine030228 respiratory systemDouble-Blind Methodmedicine030212 general & internal medicineTiotropium Bromidebusinessmedicine.drugHuman
researchProduct

Disease awareness in patients with COPD: measurement and extent

2018

Ilaria Baiardini,1 Paola Rogliani,2 Pierachille Santus,3 Angelo G Corsico,4 Marco Contoli,5 Nicola Scichilone,6 Fabiano Di Marco,7 Patrizia Lessi,8 Carla Scognamillo,8 Giorgia Molinengo,9 Fabio Ferri,10 Vincenzo Patella,11 Giuseppe Fiorentino,12 Mauro Carone,13 Fulvio Braido14 1Department of Biomedical Sciences, Humanitas University, Milan, Italy; 2Respiratory Unit, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy; 3Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Milan, Italy; 4Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; 5Department of Medical Sciences, University of F…

MaleHealth Knowledge Attitudes PracticeTime Factorspatient satisfactionSettore MED/10 - Malattie dell'Apparato RespiratorioDiseaseSeverity of Illness IndexPulmonary Disease Chronic Obstructive0302 clinical medicineCost of IllnessSurveys and QuestionnairesActivities of Daily Living80 and overawareness030212 general & internal medicineLungIllness BehaviorAged 80 and overPracticeCOPDHealth PolicyHealth KnowledgeGeneral MedicineMiddle AgedItalyFemalePublic HealthPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtySocio-culturaleInternational Journal of Chronic Obstructive Pulmonary DiseasePulmonary DiseaseTreatment satisfactionIllness perceptions03 medical and health sciencesNegatively associatedAwareness; COPD; Patient satisfaction; Questionnaire; Activities of Daily Living; Aged; Aged 80 and over; Cost of Illness; Dyspnea; Female; Humans; Illness Behavior; Italy; Lung; Male; Middle Aged; Patient Compliance; Patient Satisfaction; Pulmonary Disease Chronic Obstructive; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Awareness; Health Knowledge Attitudes Practice; Patient Acceptance of Health CaremedicineHumansCOPDIn patientAgedlcsh:RC705-779business.industryquestionnaireEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAwareneReproducibility of Resultslcsh:Diseases of the respiratory systemPatient Acceptance of Health Caremedicine.diseaseCOPD; awareness; patient satisfaction; questionnaireawareness; COPD; patient satisfaction; questionnaire; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational HealthClinical trialDyspnea030228 respiratory systemClinical Trial ReportAttitudesPhysical therapyPatient CompliancePatient awarenessbusiness
researchProduct

Corrigendum to “Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?” [YPUPT 31C (2015) 63–67]

2015

NA

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryInhalerBiochemistry (medical)MedicinePharmacology (medical)asthmaSettore MED/10 - Malattie Dell'Apparato RespiratorioRespiratory systembusinessIntensive care medicineAffect (psychology)Pulmonary Pharmacology & Therapeutics
researchProduct

Choosing wisely: Practical considerations on treatment efficacy and safety of asthma in the elderly

2015

The prevalence of asthma in the most advanced ages is similar to that of younger ages. However, the concept that older individuals may suffer from allergic asthma has been largely denied in the past, and a common belief attributes to asthma the definition of "rare" disease. Indeed, asthma in the elderly is often underdiagnosed or diagnosed as COPD, thus leading to undertreatment of improper treatment. This is also due to the heterogeneity of clinical and functional presentations of geriatric asthma, including the partial loss of reversibility and the lower occurrence of the allergic component in this age range. The older asthmatic patients are also characterized the coexistence of comorbid …

Allergymedicine.medical_specialtyAgingAllergyImmunologyAlternative medicineDiseaseReviewSettore MED/10 - Malattie Dell'Apparato RespiratorioAging; Allergy; Asthma; TherapymedicineImmunology and AllergyIntensive care medicineMolecular BiologyNon pharmacologicalAsthma...COPDbusiness.industryAging; Allergy; Asthma; Therapy; Molecular Biology; Immunology and Allergy; ImmunologySettore MED/09 - MEDICINA INTERNAmedicine.diseaseTreatment efficacyAsthmarespiratory tract diseasesClinical trialImmunologyTherapybusiness
researchProduct

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine

2017

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide, whose burden is expected to increase in the next decades, because of numerous risk factors, including the aging of the population. COPD is both preventable and treatable by an effective management including risk factor reduction, prevention, assessment, and treatment of acute exacerbations and co-morbidities. The available agents approved for COPD treatment are long-acting or ultra-long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) bronchodilators, as well as inhaled corticosteroids (ICS) in combination with LABAs. ICS use has been restricted only to selected COPD patients by th…

Settore MED/10 - Malattie dell'Apparato RespiratorioAlternative medicineCOPD; drivers; inhaled corticosteroids; prescribing; Pulmonary and Respiratory MedicineCOPD; drivers; inhaled corticosteroids; prescribingAdrenal Cortex HormonePulmonary Disease Chronic Obstructive0302 clinical medicineAdrenal Cortex HormonesDrug Combination030212 general & internal medicinePractice Patterns Physicians'Precision Medicineeducation.field_of_studyCOPDEvidence-Based MedicineprescribingdriversBronchodilator AgentsDrug CombinationsMuscarinic AntagonistPractice Guidelines as TopicGuideline AdherenceHumanAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory Medicinemedicine.medical_specialtydriverPopulationSocio-culturaleInhaled corticosteroidsMuscarinic Antagonistsinhaled corticosteroid03 medical and health sciencesAdministration InhalationmedicineHumansCOPDMedical prescriptionRisk factorIntensive care medicineeducationAdrenergic beta-2 Receptor AgonistsBronchodilator AgentPrimary Health Carebusiness.industryPrecision medicinemedicine.disease030228 respiratory systemObservational studyinhaled corticosteroidsbusiness
researchProduct

Illness perception, mood and coping strategies in allergic rhinitis: are there differences among ARIA classes of severity?

2014

Background: This study was designed to assess if illness perception, mood state and coping strategies differ according to allergic rhinitis (AR) persistence and severity. Methods: Illness perception, mood profiles, coping behaviors and rhinitis symptoms were assessed by means of validated tools inpatients classified according to the Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines. Results: Two hundred and thirty-one patients underwent data analysis. No difference in age, sex, socio-economic status, smoking habits was detected comparing patients according to AR severity, duration or 4 ARIA classes. Patients with intermittent AR reported higher scores than those with persistent A…

Persistence (psychology)Smoking habitbusiness.industryRhinitis Allergic SeasonalCoping behaviorGeneral MedicineAllergensSettore MED/10 - Malattie Dell'Apparato RespiratorioProfile of mood statesmedicine.diseaseRhinitis AllergicSeverity of Illness IndexAsthmadyspnea rhinitis mood stateIllness perceptionsMoodCross-Sectional StudiesOtorhinolaryngologymedicineMood stateHumansbusinessAsthmaClinical psychologyRhinitis
researchProduct

Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study.

2019

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease. The severity grading systems proposed by the Global initiative for Chronic Obstructive Lung Disease (GOLD) have changed over time. The aim of the study was to evaluate if the different GOLD classifications can capture the complexity of the disease by investigating the distribution of lung function and clinical parameters across the GOLD classification systems. This was an observational, retrospective, multicentre study. COPD patients were stratified according to the GOLD severity grading proposed in the 2007, and to the ABCD assessment tool present in the 2011, and 2017 versions of the initiative. Data from body plethy…

Pulmonary and Respiratory MedicineMaleChronic Obstructivemedicine.medical_specialtyphenotypeCopd patientsSettore MED/10 - Malattie dell'Apparato RespiratorioVital CapacitySocio-culturalePulmonary diseaseSeverity gradingDiseaseGOLD documentairflow obstructionurologic and male genital diseasesSeverity of Illness IndexPulmonary Disease03 medical and health sciencesLeukocyte CountPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsInternal medicineForced Expiratory VolumemedicineCOPDHumanseosinophil030212 general & internal medicineAgedRetrospective StudiesCOPDbusiness.industryairflow obstruction COPD eosinophil GOLD document phenotypeMiddle Agedmedicine.diseaseObstructive lung diseaserespiratory tract diseasesEosinophils030228 respiratory systemItalyairflow obstruction; COPD; eosinophil; GOLD document; phenotype; Aged; Eosinophils; Female; Forced Expiratory Volume; Humans; Inspiratory Capacity; Italy; Leukocyte Count; Male; Middle Aged; Pulmonary Disease Chronic Obstructive; Retrospective Studies; Risk Factors; Severity of Illness Index; Vital CapacityObservational studyFemalesense organsbusinessCOPD; GOLD document; airflow obstruction; eosinophil; phenotypeInspiratory CapacityCOPD
researchProduct

<p>Day and Night Control of COPD and Role of Pharmacotherapy: A Review</p>

2020

The topic of 24-hour management of COPD is related to day-to-night symptoms management, specific follow-up and patients' adherence to therapy. COPD symptoms strongly vary during day and night, being worse in the night and early morning. This variability is not always adequately considered in the trials. Night-time symptoms are predictive of higher mortality and more frequent exacerbations; therefore, they should be a target of therapy. During night-time, in COPD patients the supine position is responsible for a different thoracic physiology; moreover, during some sleep phases the vagal stimulation determines increased bronchial secretions, increased blood flow in the bronchial circulation (…

medicine.medical_specialtyCOPDEveningbusiness.industryGeneral MedicineDiseasemedicine.diseaseSleep medicinerespiratory tract diseases03 medical and health sciences0302 clinical medicinePharmacotherapy030228 respiratory systemBronchiolitisInternal medicinemedicine030212 general & internal medicinebusinessDynamic hyperinflationAsthmaInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study

2019

Background: Understanding the level of patients’ satisfaction with treatment and its determinants have the potential to impact therapeutic management and clinical outcome in chronic conditions such as chronic obstructive pulmonary disease (COPD). Methods: A national, multicenter, longitudinal, observational study of COPD from 20 Italian pulmonary centers to explore patients’ satisfaction to treatment [assessed by the Treatment Satisfaction Questionnaire, 9 items (TSQM-9)] and association with clinical parameters [including dyspnea score, COPD Assessment Test (CAT) score, exacerbation rate], adherence to treatment [Morisky Medication-Taking Adherence Scale (MMAS-4)], illness perception [eval…

Pulmonary and Respiratory MedicineMaleChronic Obstructivemedicine.medical_specialtyCOPD; adherence; treatment satisfactionPulmonary diseaseSocio-culturaleTreatment resultstreatment satisfactionSettore MED/10 - Malattie Dell'Apparato RespiratorioOutcome (game theory)Medication AdherencePulmonary Disease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineSurveys and QuestionnairesAdministration InhalationSettore MED/10MedicineHumansCOPDPharmacology (medical)030212 general & internal medicineadherenceIntensive care medicineOriginal ResearchAgedlcsh:RC705-779adherence COPD treatment satisfactionbusiness.industrylcsh:Diseases of the respiratory systemMiddle AgedDyspneaInhalation030228 respiratory systemItalyPatient SatisfactionAdministrationObservational studyFemalebusinessFollow-Up Studies
researchProduct

RAPP-children: A new tool for assessing quality of life in patients with asthma and rhinitis

2020

Background: RhinAsthma Patient Perspective (RAPP) is a short, validated questionnaire for assessing health-related quality of life (HRQoL) in adult patients with comorbid asthma and rhinitis, while a paediatric version is still not available. Objective: The current study aimed to develop and validate the RAPP-children questionnaire. Methods: RAPP-children was derived by combining RhinAsthma-children subscales into five unique items. At baseline (T0) and after 30 days (T1), 150 children (6-11 years) with comorbid asthma (predominantly intermittent or mild persistent) and rhinitis were given the following: RAPP-children, RhinAsthma-children, Paediatric Asthma Quality of Life Questionnaire (PA…

Malemedicine.medical_specialtypaediatricVisual analogue scaleConcordanceassessmentImmunologyasthma;Pilot ProjectspaediatricsrhinitisCronbach's alphaQuality of lifeSurveys and QuestionnairesmedicineHumansImmunology and Allergypaediatrics;assessment;daily practiceChildrhinitis.Asthmabusiness.industryDiscriminant validitydaily practice;asthmamedicine.diseaseRhinitis Allergichumanitiesquality of life;Clinical trialConvergent validityquality of lifePhysical therapyFemalebusinessassessment; asthma; daily practice; paediatrics; quality of life; rhinitis
researchProduct

Quality standards for the management of bronchiectasis in Italy: A national audit

2016

Although historically considered a neglected disease, bronchiectasis has become a disease of renewed interest over recent decades in light of an increase in prevalence and a substantial burden on healthcare systems. In 2010, the British Thoracic Society (BTS) published guidelines on the management of bronchiectasis in adults, along with specific quality standards. To date, these represent the only quality standards available in Europe. These have been tested over a number of years in the UK with progressive improvements in the standard of care. No national guidelines are available in Italy and no indications on which guideline should be followed have been given by the Italian Society of Res…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtybronchiectasismedia_common.quotation_subjectSymptom Flare UpMedical auditSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences0302 clinical medicinemedicinePrevalenceHumansQuality (business)Pseudomonas Infections030212 general & internal medicineIntensive care medicineNational auditmedia_commonAgedMedical AuditBronchiectasisbusiness.industryMedicine (all)Middle Agedmedicine.diseaseSymptom Flare UpAnti-Bacterial AgentsPatient Care Management030228 respiratory systemItalyNeeds assessmentPseudomonas aeruginosaFemalebusinessMedicine (all); Pulmonary and Respiratory MedicineNeeds Assessment
researchProduct

Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile techn…

2019

Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second c…

AllergyAllergy:Medicina Básica [Ciências Médicas]asthma -- guidelineAllergic asthmaDECISION-MAKINGAllergic Rhinitis and Its Impact on AsthmaGUIDELINESMedical and Health SciencesMedical Records0302 clinical medicineHealth careImmunology and Allergy030212 general & internal medicineAllergic Rhinitis and Its Impact on Asthma; asthma; Change management; rhinitis; Immunology and Allergy; ImmunologyMASK-RHINITISComputingMilieux_MISCELLANEOUSRinitismobilne aplikacijeupravljanje spremembMedical recordGLOBAL STRATEGYWORK PRODUCTIVITYTelemedicinemobile applications3. Good healthAsma alérgicarhiniti1107 ImmunologyCiências Médicas::Medicina Básicaklinične potiallergic -- guidelineLife Sciences & BiomedicineHumanPATIENT PARTICIPATIONAllergic RhinitisTelemedicinemedicine.medical_specialtyanimal structuresmultimorbidityEUROPEAN INNOVATION PARTNERSHIPImmunologyChange Management[object Object]Settore MED/10 - Malattie Dell'Apparato RespiratorioAsthma/diagnosisCHRONIC DISEASESMACVIA-ARIA03 medical and health sciencesrhinitismedicinemultimorbidnostQUALITYHumanscritical pathwaysastma -- smernicaPatient participationAsmaudc:616.2AsthmaScience & TechnologyARIAbusiness.industryAllergic Rhinitis and Its Impact on Asthma; asthma; Change management; rhinitis; Change Management; Humans; Medical Records; Asthma; Multimorbidity; Rhinitis Allergic; TelemedicineSettore MED/09 - MEDICINA INTERNAchange managementMultimorbidityMobile Airways Sentinel Network (MASK) Study GroupGuidelineasthmata3121medicine.diseaseRinite alérgicaRhinitis AllergicRhinitis Allergic/diagnosisAsthmaIntegrated carealergijski rinitis -- smernicaAllergic Rhinitis and Its Impact on Asthma asthma Change management rhinitis Immunology and Allergy Immunology030228 respiratory systemFamily medicine3121 General medicine internal medicine and other clinical medicineMedical RecordClinical Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyImpact on AsthmaJournal of Allergy and Clinical Immunology
researchProduct

LABA/LAMA fixed-dose combinations in patients with COPD: A systematic review

2018

Paola Rogliani,1 Luigino Calzetta,1 Fulvio Braido,2 Mario Cazzola,1 Enrico Clini,3 Girolamo Pelaia,4 Andrea Rossi,5 Nicola Scichilone,6 Fabiano Di Marco7 1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy; 2Department of Internal Medicine, IRCCS San Martino Genoa University Hospital, Genoa, Italy; 3Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, Magna Græcia University, Catanzaro, Italy; 5Pulmonary Unit, University of Verona, Verona, Italy; 6Department of Internal Medicine, University of Palermo, Palermo, Italy; 7…

ExacerbationReviewQuinoloneslaw.inventionPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicineRandomized controlled trialsystematic reviewlaw030212 general & internal medicineCOPDLABA LAMA fixed-dose combination COPD systematic reviewbiologyHealth PolicyOlodaterolLAMAGeneral MedicineLamaRespiratory Function Testsfixed-dose combinationDrug CombinationsTreatment OutcomeIndanssystematic review.hormones hormone substitutes and hormone antagonistsmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyFixed-dose combinationLABA; LAMA; fixed-dose combination; COPD; systematic reviewLABAMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicinemedicineHumansCOPDAdverse effectAdrenergic beta-2 Receptor Agonistslcsh:RC705-779business.industryPublic Health Environmental and Occupational Healthlcsh:Diseases of the respiratory systemCOPD; LABA; LAMA; fixed-dose combination; systematic reviewmedicine.diseasebiology.organism_classificationGlycopyrrolate030228 respiratory systemchemistryDelayed-Action PreparationsIndacaterolbusiness
researchProduct

Genuair® Usability Test: Results of a National Public Survey of the Elderly

2016

Proper use of inhaler devices may be problematic in elderly patients due to age-related difficulties. A survey was administered to elderly patients to investigate the usability of the Genuair® device and patients' subjective viewpoint on the device. A representative sample of the Italian population aged ≥ 65 years was completed with a pre-defined sample of 89 patients with hand arthritis/arthrosis. Of 526 respondents, 88 were not self-sufficient. Only the replies of the 438 self-sufficient respondents were analyzed. A total of 107 participants (24%) reported having respiratory diseases, and 81 of these (76%) were users of inhaler devices. After the first test, the device was considered “pra…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorsSample (statistics)Settore MED/10 - Malattie Dell'Apparato Respiratorioelderly03 medical and health sciences0302 clinical medicinePatient satisfactionPatient Education as TopicSurveys and QuestionnairesmedicineHumansadherence030212 general & internal medicineAgedAged 80 and overbusiness.industryArthritisNebulizers and VaporizersInhalerUsabilityPublic surveyadherence; elderly; inhaler device; usability; Pulmonary and Respiratory MedicineHandItalian populationTest (assessment)usabilityItaly030228 respiratory systemPatient SatisfactionHand arthritisPhysical therapyinhaler deviceFemalebusinessCOPD: Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Late Breaking Abstract - Validation of a tool for the assessment of disease awareness (DA) in COPD

2017

Background: DA could influence adherence to treatment and outcomes. No validated tools are available to assess DA in COPD Aims: To generate a tool able to explore DA in COPD patients, the Disease Awareness in COPD Questionnaire (DACQ) Methods: A 2-step Delphi approach was used to develop a questionnaire that was tested for validity in a cohort of COPD patients of an Italian observational, multicenter, prospective study (SAT study - NCT02689492) Results: Consensus on a 27-item provisional questionnaire was obtained with 2 Delphi rounds. Factor analysis showed a 4-factor solution accounting for 35% of variance; each factor (disease acceptance, awareness of treatment needs, disease knowledge, …

COPDmedicine.medical_specialtyRasch modelbusiness.industryDelphi methodmedicine.diseaseSpearman's rank correlation coefficientCronbach's alphaCohortmedicinePhysical therapyObservational studybusinessProspective cohort studyEpidemiology
researchProduct

Exhaled nitric oxide is associated with cyclic changes in sexual hormones

2013

Abstract Background We hypothesized that changes in the levels of sexual hormones during the menstrual cycle influence the concentration of nitric oxide in the exhaled air (FeNO) and alveolar exhaled nitric oxide (CANO). Methods Twelve healthy, non allergic women in their reproductive age (age range 25–37 years) were recruited. Subjects were studied, on alternate days, over the course of their menstrual cycle. At each visit, measurements of FeNO and CANO were performed. Progesterone and 17-β-estradiol concentrations were measured in salivary samples. Results Eight subjects completed the study. The levels of FeNO and CANO were 13 ± 4.7 pbb and 3.5 ± 1.9 pbb, respectively (mean ± SD). The mea…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedia_common.quotation_subjectReproductive ageBronchiSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideNitric oxidechemistry.chemical_compoundsexual hormonesInternal medicinemedicineHumansPharmacology (medical)SalivaGeneralized estimating equationMenstrual cycleMenstrual CycleProgesteronemedia_commonEstradiolbusiness.industryBiochemistry (medical)GenderBiomarkerHormonesSexual hormonesPulmonary AlveoliEndocrinologychemistryBreath TestsNon allergicExhaled nitric oxideAirway inflammation; Biomarker; Gender; Hormones; Adult; Breath Tests; Bronchi; Estradiol; Female; Humans; Menstrual Cycle; Nitric Oxide; Progesterone; Pulmonary Alveoli; Saliva; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical)FemalebusinessHormoneAirway inflammation
researchProduct

Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view.

2014

Randomized Controlled Trials (RCTs) are the "gold standard" for evaluating treatment outcomes providing information on treatments "efficacy". They are designed to test a therapeutic hypothesis under optimal setting in the absence of confounding factors. For this reason they have high internal validity. The strict and controlled conditions in which they are conducted, leads to low generalizability because they are performed in conditions very different from real life usual care. Conversely, real life studies inform on the "effectiveness" of a treatment, that is, the measure of the extent to which an intervention does what is intended to do in routine circumstances. At variance to RCTs, real …

Pulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyAsthma; COPD; Randomized controlled trials; Real life studies; Asthma; Confounding Factors (Epidemiology); Humans; Pulmonary Disease Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)Alternative medicineSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionPulmonary DiseasePulmonary Disease Chronic ObstructiveRandomized controlled triallawIntervention (counseling)medicineCOPDHumansPharmacology (medical)Generalizability theoryMedical physicsInternal validityReal life studiesRandomized Controlled Trials as Topicbusiness.industryBiochemistry (medical)Gold standardConfounding Factors EpidemiologicVariance (accounting)Confounding Factors (Epidemiology)AsthmaReal life studieRandomized controlled trials; Real life studies; Asthma; COPDRandomized controlled trialResearch DesignRandomized controlled trialsPhysical therapybusinessStrengths and weaknesses
researchProduct

RHINASTHMA-Children: A new quality of life tool for patients with respiratory allergy

2017

Background Specific instruments for health-related quality of life (HRQoL) assessment in adolescents with rhinoconjunctivitis or asthma are available. None of them evaluates rhinitis and asthma together, although they often coexist. Our aim was to validate a HRQoL questionnaire for adolescents with rhinoconjunctivitis, asthma, or both. Methods A pool of 38 items covering the main symptoms and problems related to respiratory allergy was generated based on literature review, clinical experience, and unstructured interviews to 54 adolescents. The items were randomly listed and presented to 88 consecutive outpatients (44 M; mean age 15.2 ± 3.1). Patients had to indicate which item they had expe…

Malemedicine.medical_specialtyPsychometricsImmunologyPediatrics03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesInternal consistencymedicineHumansImmunology and AllergyIn patient030212 general & internal medicineYoung adultChildReliability (statistics)Asthmabusiness.industryRHINITISReproducibility of ResultsRespiratory allergyPerinatology and Child Healthmedicine.diseaseRhinitis AllergicAsthma030228 respiratory systemScale (social sciences)Pediatrics Perinatology and Child HealthQuality of LifePhysical therapyFemalePediatrics Perinatology and Child Health; Immunology and Allergy; ImmunologyFactor Analysis StatisticalbusinessPediatric Allergy and Immunology
researchProduct

RhinAsthma patient perspective: a short daily asthma and rhinitis QoL assessment.

2012

Background The present study aimed to develop a short validated patient-completed questionnaire, the RhinAsthma Patient Perspective (RAPP), to assess the health-related quality of life (HRQoL) in patients with asthma and comorbid allergic rhinitis in clinical practice. Methods A provisional RAPP questionnaire was formed from candidate items identified through retrospective analysis of 333 RHINASTHMA questionnaires. This was then tested on 150 asthma patients with allergic rhinitis. Results Psychometric analyses identified eight items fitting a unidimensional model to form RAPP. Internal consistency (Cronbach's alpha coefficient > 0.8) and agreement with RHINASTHMA (r = −0.31, P = 0.0001) we…

AdultMalemedicine.medical_specialtyRhinitis Allergic PerennialPsychometricsAdolescentPsychometricsVisual analogue scaleassessmentConcordanceImmunologyPopulationSettore MED/10 - Malattie Dell'Apparato RespiratoriorhinitisAllergicCronbach's alphaQuality of lifeSurveys and Questionnaires80 and overmedicineSurveys and QuestionnaireImmunology and AllergyHumansdaily practiceeducationAsthmaAgedAged 80 and overeducation.field_of_studybusiness.industryassessment; asthma; daily practice; quality of life; rhinitis; Adolescent; Adult; Aged; Aged 80 and over; Asthma; Female; Humans; Male; Middle Aged; Psychometrics; Rhinitis Allergic; Rhinitis Allergic Perennial; Quality of Life; Surveys and Questionnaires; Immunology and Allergy; ImmunologyMiddle Agedmedicine.diseasePerennialRhinitis AllergichumanitiesAsthmarhinitiConvergent validityassessment; asthma; daily practice; quality of life; rhinitisPhysical therapyQuality of LifeFemalebusinessPsychometricHumanAllergy
researchProduct

Author_Response_1 – Supplemental material for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observat…

2019

Supplemental material, Author_Response_1 for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study by Marco Contoli, Paola Rogliani, Fabiano Di Marco, Fulvio Braido, Angelo G. Corsico, Christian A. Amici, Roberto Piro, Riccardo Sarzani, Patrizia Lessi, Carla Scognamillo, Nicola Scichilone and Pierachille Santus in Therapeutic Advances in Respiratory Disease

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct

Day and Night Control of COPD and Role of Pharmacotherapy: A Review

2020

Abstract The topic of 24-hour management of COPD is related to day-to-night symptoms management, specific follow-up and patients’ adherence to therapy. COPD symptoms strongly vary during day and night, being worse in the night and early morning. This variability is not always adequately considered in the trials. Night-time symptoms are predictive of higher mortality and more frequent exacerbations; therefore, they should be a target of therapy. During night-time, in COPD patients the supine position is responsible for a different thoracic physiology; moreover, during some sleep phases the vagal stimulation determines increased bronchial secretions, increased blood flow in the bronchial circ…

nightLABAReviewMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratoriocopd – symptoms – dyspnea – night – sleep – follow-up – adherence – circadian lama – laba – icsAdherence; Circadian; COPD; Dyspnea; Follow-up; Night; Sleep; SymptomsPulmonary Disease Chronic ObstructiveAdrenal Cortex HormonesAdministration InhalationSettore MED/10follow-upCOPDHumansadherencesleepAdrenergic beta-2 Receptor Agonistslcsh:RC705-779Circadianlcsh:Diseases of the respiratory systemdyspnearespiratory tract diseasesBronchodilator Agentscircadian LAMAICSsymptomsAdherence Circadian COPD Dyspnea Follow-up Night Sleep SymptomsInternational Journal of COPD
researchProduct

Reviewer_2_v.1 – Supplemental material for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observation…

2019

Supplemental material, Reviewer_2_v.1 for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study by Marco Contoli, Paola Rogliani, Fabiano Di Marco, Fulvio Braido, Angelo G. Corsico, Christian A. Amici, Roberto Piro, Riccardo Sarzani, Patrizia Lessi, Carla Scognamillo, Nicola Scichilone and Pierachille Santus in Therapeutic Advances in Respiratory Disease

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct

Recommendations for assessing Patient-Reported Outcomes and Health-Related quality of life in clinical trials on allergy: a GA2LEN taskforce position…

2010

The aim of this Global Allergy and Asthma European Network (GA(2)LEN) consensus report is to provide recommendations for patient-reported outcomes (PROs) evaluation in clinical trials for allergic diseases, which constitute a global health problem in terms of physical, psychological economic and social impact. During the last 40 years, PROs have gained large consideration and use in the scientific community, to gain a better understanding of patients' subjective assessment with respect to elements concerning their health condition. They include all health-related reports coming from the patient, without involvement or interpretation by physician or others. PROs assessment should be performe…

medicine.medical_specialtyPediatricsImmunologyPopulationMEDLINEAlergiaHypersensitivity; Humans; Treatment Outcome; Clinical Trials as Topic; Quality of Life; Outcome Assessment (Health Care); Data CollectionOutcome Assessment (Health Care)Quality of life (healthcare)Outcome Assessment Health CareGlobal healthmedicineHypersensitivityHumansImmunology and AllergyeducationAsmaeducation.field_of_studyClinical Trials as Topicbusiness.industryData CollectionGa2LenGuidelinehumanitiesClinical trialTreatment OutcomeFamily medicineInclusion and exclusion criteriaQuality of LifePosition paperbusinessQualidade de VidaHuman
researchProduct

Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives

2018

Alicia Padilla Galo,1,* Marina Labor,2,3,* Angelica Tiotiu,4 Ilaria Baiardini,5 Nicola Scichilone,6 Fulvio Braido7 1Unit of Pneumology, Agencia Sanitaria Costa del Sol, Marbella, Málaga, Spain; 2Department of Pulmonology, University Hospital Center Osijek, Osijek, Croatia; 3Faculty of Medicine, J.J. Strossmayer University of Osijek, Osijek, Croatia; 4Department of Pulmonology, CHRU Nancy, DevAH – Development, Adaptation and Disadvantage, Cardiorespiratory Regulations and Motor Control, University of Lorraine, Nancy, France; 5Department of Biomedical Sciences, Humanitas University, Milan, Italy; 6Department of Biomedicine and Internal and Specialistic Medicine (DIBIMIS),…

Patient Related Outcome MeasuresPatient Related Outcome Measures
researchProduct

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

2018

Paola Rogliani,1 Luigino Calzetta,1 Fulvio Braido,2 Mario Cazzola,1 Enrico Clini,3 Girolamo Pelaia,4 Andrea Rossi,5 Nicola Scichilone,6 Fabiano Di Marco7 1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy; 2Department of Internal Medicine, IRCCS San Martino Genoa University Hospital, Genoa, Italy; 3Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, Magna Græcia University, Catanzaro, Italy; 5Pulmonary Unit, University of Verona, Verona, Italy; 6Department of Internal Medicine, University of Palermo, Palermo, Ital…

International Journal of Chronic Obstructive Pulmonary Diseasehormones hormone substitutes and hormone antagonistsInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Contoli_et_al_Additional_file20190924 – Supplemental material for Satisfaction with chronic obstructive pulmonary disease treatment: results from a m…

2019

Supplemental material, Contoli_et_al_Additional_file20190924 for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study by Marco Contoli, Paola Rogliani, Fabiano Di Marco, Fulvio Braido, Angelo G. Corsico, Christian A. Amici, Roberto Piro, Riccardo Sarzani, Patrizia Lessi, Carla Scognamillo, Nicola Scichilone and Pierachille Santus in Therapeutic Advances in Respiratory Disease

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct

Reviewer_1_v.1 – Supplemental material for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observation…

2019

Supplemental material, Reviewer_1_v.1 for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study by Marco Contoli, Paola Rogliani, Fabiano Di Marco, Fulvio Braido, Angelo G. Corsico, Christian A. Amici, Roberto Piro, Riccardo Sarzani, Patrizia Lessi, Carla Scognamillo, Nicola Scichilone and Pierachille Santus in Therapeutic Advances in Respiratory Disease

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life

2016

Marco Contoli,1 Paolo Solidoro,2 Fabiano Di Marco,3,4 Nicola Scichilone,5 Angelo Corsico,6 Fulvio Braido,7 Pierachille Santus4,8 1Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 2Cardiovascular and Thoracic Department, Città della Salute, Turin, Italy; 3Department of Health Sciences, University of Milan, Milan, Italy; 4Respiratory Unit, San Paolo Hospital, Milan, Italy; 5Department of Internal Medicine, Section of Pulmonology (DIBIMIS), University of Palermo, Palermo, Italy; 6Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 7Allergy and Respiratory Diseases Clinic, DIMI, University …

International Journal of Chronic Obstructive Pulmonary DiseaseInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19

2021

International audience; Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe, or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage have been associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2). As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT1 R) axis associated with oxidative stress. This leads to insulin resistance …

ARIA groupAntioxidantMediterranean dietmedicine.medical_treatmentBrassicasulforaphaneMESH: Angiotensin-Converting Enzyme 2ReviewcabbageAntioxidants0302 clinical medicine10183 Swiss Institute of Allergy and Asthma ResearchVegetableskimchiFood sciencekimči0303 health sciencesMESH: NF-E2-Related Factor 23. Good healthAngiotensin-converting enzyme 22723 Immunology and Allergyfermentirana zelenjavaMESH: EcologyKeywords: Angiotensin converting enzyme 2NF-E2-Related Factor 2KEAP1-NRF2 SYSTEMImmunologyReviewsBrassicaNRF203 medical and health sciencesudc:578:635.34:663.15:COVID‐19angiotensin-converting enzyme 2CorrespondenceHumansMESH: SARS-CoV-2LactobacilluINTERMITTENT HYPOXIA2403 ImmunologyScience & TechnologyMESH: HumansAngiotensin II receptor type 1koronavirusMESH: Antioxidantsmedicine.disease030228 respiratory systemchemistryFermentationAllergymedicine.disease_causechemistry.chemical_compoundLINKING GUT MICROBIOTALactobacillalesLactobacillusImmunology and AllergyMESH: COVID-19Angiotensin converting enzyme 2030212 general & internal medicineOXIDATIVE STRESS[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyKeywords: Angiotensin converting enzyme 2; COVID-19; Lactobacillus; cabbage; diet; fermented vegetable; kimchi; sulforaphane.angiotensin-converting enzyme 2; cabbage; COVID-19; diet; fermented vegetable; kimchi; Lactobacillus; sulforaphane2. Zero hungerFOODSEcologyLactobacillalesMortality rate10177 Dermatology ClinicMEDITERRANEAN DIET1107 ImmunologyLife Sciences & Biomedicinefermented vegetable610 Medicine & healthSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologyMESH: FermentationMESH: Gastrointestinal MicrobiomeInsulin resistanceMESH: DietDownregulation and upregulationmedicine030304 developmental biologySARS-CoV-2COVID-19MESH: BrassicaCOVID-19; Lactobacillus; angiotensin-converting enzyme 2; cabbage; diet; fermented vegetable; kimchi; sulforaphane; Angiotensin-Converting Enzyme 2; Antioxidants; COVID-19; Diet; Ecology; Gastrointestinal Microbiome; Humans; Lactobacillales; NF-E2-Related Factor 2; Brassica; Fermentation; SARS-CoV-2; Vegetablesbiology.organism_classificationMESH: VegetablesDYSFUNCTIONDietGastrointestinal MicrobiomeLactobacillusMESH: Lactobacillalesangiotensin-converting enzyme 2 cabbage COVID-19 diet fermented vegetable kimchi Lactobacillus sulforaphanedietOxidative stressSulforaphane
researchProduct

Beliefs and preferences regarding biological treatments for severe asthma

2020

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers’ specialty and experience. Methods: We conducted an online survey composed of 35 questions in English. The survey was circulated via the INterasma Scientific Network (INESNET) platform as well as throu…

Severe asthmaBehavior; Belief; Biological drug; Severe asthmainterleukine 5 IgEMULTICENTERDiseaseOmalizumabADD-ON THERAPYBehavior Belief Biological drug Severe asthmaDOUBLE-BLIND0302 clinical medicineMedicine and Health SciencesImmunology and AllergyEosinophil IL5 [Eos]030223 otorhinolaryngologyPulmonologistssevere asthma biological drug belief behavior3. Good healthBeliefSAFETYmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyEos: Eosinophil IL5ImmunologyBiological drugSpecialtylong-acting beta2-agonist OMASocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioArticle03 medical and health sciencesQuality of life (healthcare)Omalizumab. OMA/IL5 Omalizumab plus anti-IL5 moleculeOMALIZUMABmedicineIntensive care medicineAsthmaBehaviorINterasma Scientific Network LABAbusiness.industryMEPOLIZUMABmedicine.diseaseEFFICACYICS inhaled corticosteroidsLIFE030228 respiratory systemImmunoglobulin E INESNETAllergistslcsh:RC581-607businessMepolizumab
researchProduct

Chronic obstructive lung disease “expert system”: Validation of a predictive tool for assisting diagnosis

2018

Purpose: The purposes of this study were development and validation of an expert system (ES) aimed at supporting the diagnosis of chronic obstructive lung disease (COLD). Methods: A questionnaire and a WebFlex code were developed and validated in silico. An expert panel pilot validation on 60 cases and a clinical validation on 241 cases were performed. Results: The developed questionnaire and code validated in silico resulted in a suitable tool to support the medical diagnosis. The clinical validation of the ES was performed in an academic setting that included six different reference centers for respiratory diseases. The results of the ES expressed as a score associated with the risk of su…

Pulmonary and Respiratory MedicineChronic ObstructivePilot ProjectsExpert SystemsSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary DiseasePulmonary Disease Chronic ObstructiveSoftware DesignSurveys and QuestionnairesChronic obstructive lung diseaseDiagnosisSurveys and QuestionnaireHumansAge FactorPilot ProjectExpert SystemChronic obstructive lung diseasesAgedHealth PolicyEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthMethodologyAge FactorsChronic obstructive lung diseases Diagnosis Expert systems Pulmonary and Respiratory Medicine Health Policy Public Health Environmental and Occupational HealthMiddle AgedAsthmaCoughSpirometrySample SizeChronic DiseasePublic HealthChronic obstructive lung diseases; Diagnosis; Expert systems; Age Factors; Aged; Asthma; Chronic Disease; Cough; Humans; Middle Aged; Pilot Projects; Pulmonary Disease Chronic Obstructive; Sample Size; Spirometry; Expert Systems; Software Design; Surveys and QuestionnairesDiagnosiHuman
researchProduct

Supplementary_Material – Supplemental material for Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD…

2018

Supplemental material, Supplementary_Material for Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD treatment (SAT) study by Carlo Lazzaro, Fabiano Di Marco, Nicola Scichilone, Fulvio Braido, Marco Contoli, Paola Rogliani, Pierachille Santus, Valentina Acciai, Carla Scognamillo, Irene Olivi and Angelo Guido Corsico in Global & Regional Health Technology Assessment

111708 Health and Community ServicesFOS: Health sciences
researchProduct